← All indications
Condylomata Acuminata
Sexually transmitted form of anogenital warty growth caused by the HUMAN PAPILLOMAVIRUS VIRUSES.
Subtype terms (1)
More specific conditions that are subtypes of Condylomata Acuminata in the MeSH hierarchy.
Drugs by status
Approved for this indication (6)
Phase 4 trials (5)
Phase 3 trials (10)
Phase 2 trials (15)
Organizations
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (18)
- Merck
- Catalysis SL
- Graceway
- Laboratorio Elea S.A.C.I.F. y A.
- Shanghai Bovax Biotechnology Co., Ltd.
- bioRASI, LLC
- Huazhong University of Science and Technology
- University of Pretoria
- Assiut University
- Laval University
- Solano Clinical Research
- Centre for Vaccinology, Halifax
- Stellenbosch University
- Government of British Columbia
- Assistance Publique - Hôpitaux de Paris
- Hyloris Developments SA
- Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
- Calox
Organization Involved with Phase 2 Indications (24)
- PPD
- ProStraken
- Novartis
- Anaconda Pharma
- Aviragen Therapeutics
- BioMAS Ltd
- Cutanea Life Sciences, Inc.
- G&E Herbal Biotechnology Co., LTD
- Novan, Inc.
- Tamir Biotechnology, Inc.
- Verrica Pharmaceuticals Inc.
- ViroXis Corporation
- National Cheng Kung University
- University of Aberdeen
- University of Copenhagen
- Leiden University
- Technion University
- Progressive Clinical Research
- Indiana Clinical Trials Center
- Erasmus University Rotterdam
- Paidion Research, Inc
- Instat services
- BioClinica, Inc.
- Leo Pharma
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (4)